- Home
- CTLP vs REPL Comparison
CTLP vs REPL Comparison
Compare CTLP & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTLP
- REPL
- Stock Information
- Founded
- CTLP 1992
- REPL 2015
- Country
- CTLP United States
- REPL United States
- Employees
- CTLP N/A
- REPL N/A
- Industry
- CTLP EDP Services
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- CTLP Technology
- REPL Health Care
- Exchange
- CTLP Nasdaq
- REPL Nasdaq
- Market Cap
- CTLP 574.8M
- REPL 578.4M
- IPO Year
- CTLP N/A
- REPL 2018
- Fundamental
- Price
- CTLP $8.47
- REPL $8.35
- Analyst Decision
- CTLP Strong Buy
- REPL Strong Buy
- Analyst Count
- CTLP 4
- REPL 6
- Target Price
- CTLP $12.50
- REPL $20.00
- AVG Volume (30 Days)
- CTLP 590.7K
- REPL 1.4M
- Earning Date
- CTLP 05-08-2025
- REPL 05-22-2025
- Dividend Yield
- CTLP N/A
- REPL N/A
- EPS Growth
- CTLP 404.65
- REPL N/A
- EPS
- CTLP 0.80
- REPL N/A
- Revenue
- CTLP $292,642,000.00
- REPL N/A
- Revenue This Year
- CTLP $16.51
- REPL $31.16
- Revenue Next Year
- CTLP $15.36
- REPL N/A
- P/E Ratio
- CTLP $10.59
- REPL N/A
- Revenue Growth
- CTLP 12.51
- REPL N/A
- 52 Week Low
- CTLP $5.82
- REPL $4.92
- 52 Week High
- CTLP $11.36
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- CTLP 56.30
- REPL 48.96
- Support Level
- CTLP $8.16
- REPL $6.84
- Resistance Level
- CTLP $8.80
- REPL $9.85
- Average True Range (ATR)
- CTLP 0.38
- REPL 1.04
- MACD
- CTLP 0.06
- REPL 0.13
- Stochastic Oscillator
- CTLP 73.17
- REPL 48.40
About CTLP Cantaloupe Inc.
Cantaloupe Inc operates in the small ticket electronic payments industry. It provides wireless, cashless, micro-transactions, and networking services within the unattended Point of Sale (POS) market. Its products and services portfolio consists of ePort Cashless devices, eSuds, EnergyMisers, and Value-added services which include Loyalty and Prepaid, Intelligent Vending, and others. The company offers services to different industries covering car wash, taxi and transportation, laundry, vending, kiosk, amusement, and arcade. The company derives revenue from the sale or lease of equipment and services to the small ticket, unattended POS market, and the majority of its revenue is derived from subscription and transaction fees.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.